AMA Urges FDA to Apply Stricter Scientific Standards to Botanical Products
What happened
The American Medical Association sent a letter to the Food and Drug Administration urging increased regulation of botanical products. The AMA recommends that the FDA hold products derived from substances such as cannabis and kratom to the same scientific standards used for conventional drugs. The AMA noted that consumers are facing risks, including dependence and overdose, from these products being used without research-based evidence.
From healio.com
Why it matters
This push for stricter regulation could change how botanical products are marketed and sold in the United States. If the FDA adopts these standards, it would require manufacturers to undergo clinical trials to determine efficacy and safety. This shift could impact the supply and costs of botanical health products.
From healio.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AMASpeculative
Botanical manufacturers might face increased costs related to research and clinical trials if the FDA adopts stricter standards.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- DEA may face increased enforcement demands over botanical productsDEA may face increased enforcement demands as FDA considers stricter botanical drug rulesLikely
- Stricter botanical rules may require Congressional action on FDA fundingCongress may face pressure to adjust FDA scope and funding for botanical productsPossible
- Stricter FDA standards may raise compliance costs for Eli LillyStricter FDA standards could increase compliance costs for Eli Lilly and CompanyPossible
- Stricter standards may require Center for Drug Evaluation and Research updatesStricter standards may require Center for Drug Evaluation and Research updatesPossible
- How could AMA's push for stricter botanical regulation affect the Department of Health & Human Services?HHS oversight may increase as AMA pushes for stricter botanical drug regulationPossible